HepatiCan Presents Bioartificial Liver Findings at ESOT 2025

HepatiCan presented new data at ESOT 2025 highlighting the continued development of its cryopreservable bioartificial liver system for patients with liver failure.

The presentation showcased how the HepatiCan platform successfully delivered temporary liver support using approximately 70 billion human liver organoid cells at clinical scale. Designed for bedside use in intensive care units, the system was shown to maintain cell viability and metabolic activity over a 72-hour testing period while operating at clinically relevant plasma flow rates.

Researchers also reported that the device met international electrical and mechanical safety standards and was designed to integrate with existing hospital apheresis systems.

The findings demonstrated the potential for HepatiCan to support patients with acute or decompensated liver failure by temporarily providing liver function while allowing time for recovery, transplantation, or emerging therapies to take effect.

The ESOT 2025 presentation marked another significant milestone in the advancement of the HepatiCan bioartificial liver platform and its potential role as an alternative or bridge to liver transplantation.